Malaria vaccine based on self-assembling protein nanoparticles

Expert Review of Vaccines

Volumn 14, Issue 12, 2015, Pages 1523-1527

  Burkhard, Peter ^a   Lanar, David E ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Malaria; Nanoparticle; Plasmodium falciparum; SAPN; Vaccine

Indexed keywords

MALARIA VACCINE; NANOPARTICLE; SELF ASSEMBLING PROTEIN NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; EPITOPE; PARASITE ANTIGEN; PROTOZOON ANTIBODY; SUBUNIT VACCINE;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CROSS PRESENTATION; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; LARGE SCALE PRODUCTION; LONG TERM MEMORY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; VIRUS LIKE AGENT; IMMUNOLOGY; MALARIA, FALCIPARUM; METABOLISM; PLASMODIUM FALCIPARUM;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DRUG CARRIERS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; NANOPARTICLES; PLASMODIUM FALCIPARUM; VACCINES, SUBUNIT;

EID: 84947039786     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1096781     Document Type: Review

References (20)

1. Heppner DG Jr. , Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based, multistage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23(17-18):2243-2250.
2. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. New Engl J Med. 2011;365(20): 1863-1875.
3. Aide P, Dobano C, Sacarlal J, et al. Four year immunogenicity of the RTS,S/AS02 (A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine. 2011;29(35):6059-6067.
4. Mian-McCarthy S, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New Engl J Med. 2012;367(24):2284-2295.
5. Doll TAPF, Raman S, Dey R, et al. Nanoscale assemblies and their biomedical applications. J R Soc Interface. 2013;10(80). Article ID 20120740.
6. Langer R. Drug delivery and targeting. Nature. 1998;392(6679):5-10.
7. Latham T, Galarza JM. Formation of wild-type and chimeric influenza viruslike particles following simultaneous expression of only four structural proteins. J Virol. 2001;75(13):6154-6165.
8. Kaba SA, Brando C, Guo Q, et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol. 2009;183(11):7268-7277.
9. Kaba SA, McCoy ME, Doll TA, et al. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One. 2012;7 (10):e48304.
10. Chai SK, Clavijo P, Tam JP, et al. Immunogenic properties of multiple antigen peptide systems containing defined T-epitpoe and B-epitope. J Immunol. 1992;149(7):2385-2390.
11. Mahajan B, Berzofsky JA, Boykins RA, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect Immun. 2010;78(11):4613-4624.
12. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341 (6152):1359-1365.
13. Raman S, Machaidze G, Lustig A, et al. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine. 2006;2 (2):95-102.
14. Pimentel TAPF, Yan Z, Jeffers SA, et al. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des. 2009;73(1):53-61.
15. Babapoor S, Neef T, Mittleholzer C, et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res Treat. 2011. Article ID 126794.
16. Wahome N, Pfeiffer T, Ambiel I, et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des. 2012;80 (3):349-357.
17. El Bissati K, Zhou Y, Dasgupta D, et al. Effectiveness of a novel immunogenic nanoparticle platform for toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32(26):3243-3248.
18. Schroeder U, Graff A, Buchmeier S, et al. Peptide nanoparticles serve as a powerful platform for the immunogenic display of poorly antigenic actin determinants. J Mol Biol. 2009;386(5):1368-1381.
19. McCoy ME, Golden HE, Doll TAPF, et al. Mechanisms of protective immune responses induced by the Plasmodium falciparum CSP-based self-assembling protein nanoparticle vaccine. Malar J. 2013;12(1):136.
20. Yang Y, Burkhard P. Encapsulation of gold nanoparticles into self-assembling protein nanoparticles. J Nanobiotechnol. 2012;10(1):42.